Health Canada is independently reviewing a class of drugs used in diabetes and weight-loss medications following reports that they may lead to a risk of suicide.
In an email on Friday, the federal department told CBC News that it would be doing an assessment of Canadian and international data that looks at the risk of suicidal thoughts, self-harm and suicide when it comes to a class of drugs known as GLP-1 receptor agonists.
“Health Canada continues to monitor all side-effects of marketed health products … to help ensure that the benefits of the product continue to outweigh the risks,” the statement says.
The decision comes
